BR112020020567A2 - Forma de dosagem sólida de múltiplos particulados que tem uma textura elástica - Google Patents
Forma de dosagem sólida de múltiplos particulados que tem uma textura elástica Download PDFInfo
- Publication number
- BR112020020567A2 BR112020020567A2 BR112020020567-2A BR112020020567A BR112020020567A2 BR 112020020567 A2 BR112020020567 A2 BR 112020020567A2 BR 112020020567 A BR112020020567 A BR 112020020567A BR 112020020567 A2 BR112020020567 A2 BR 112020020567A2
- Authority
- BR
- Brazil
- Prior art keywords
- dosage form
- solid
- particulate
- mixture
- microcapsules
- Prior art date
Links
- 239000007909 solid dosage form Substances 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 84
- 239000003094 microcapsule Substances 0.000 claims abstract description 74
- 239000002552 dosage form Substances 0.000 claims abstract description 60
- 239000007787 solid Substances 0.000 claims abstract description 57
- 229920002472 Starch Polymers 0.000 claims abstract description 45
- 235000019698 starch Nutrition 0.000 claims abstract description 45
- 239000008107 starch Substances 0.000 claims abstract description 44
- 239000002245 particle Substances 0.000 claims abstract description 23
- 238000005266 casting Methods 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940079593 drug Drugs 0.000 claims abstract description 13
- 239000011785 micronutrient Substances 0.000 claims abstract description 13
- 235000013369 micronutrients Nutrition 0.000 claims abstract description 13
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 12
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 11
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 11
- 108010010803 Gelatin Proteins 0.000 claims description 9
- 229920000159 gelatin Polymers 0.000 claims description 9
- 239000008273 gelatin Substances 0.000 claims description 9
- 235000019322 gelatine Nutrition 0.000 claims description 9
- 235000011852 gelatine desserts Nutrition 0.000 claims description 9
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 8
- 229920001661 Chitosan Polymers 0.000 claims description 8
- 229920000084 Gum arabic Polymers 0.000 claims description 8
- 229920000388 Polyphosphate Polymers 0.000 claims description 8
- 235000010489 acacia gum Nutrition 0.000 claims description 8
- 239000000205 acacia gum Substances 0.000 claims description 8
- 229940072056 alginate Drugs 0.000 claims description 8
- 235000010443 alginic acid Nutrition 0.000 claims description 8
- 229920000615 alginic acid Polymers 0.000 claims description 8
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 8
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 8
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 8
- 235000010418 carrageenan Nutrition 0.000 claims description 8
- 239000000679 carrageenan Substances 0.000 claims description 8
- 229920001525 carrageenan Polymers 0.000 claims description 8
- 229940113118 carrageenan Drugs 0.000 claims description 8
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims description 8
- 230000002209 hydrophobic effect Effects 0.000 claims description 8
- 150000002759 monoacylglycerols Chemical class 0.000 claims description 8
- 239000001814 pectin Substances 0.000 claims description 8
- 235000010987 pectin Nutrition 0.000 claims description 8
- 229920001277 pectin Polymers 0.000 claims description 8
- 150000003904 phospholipids Chemical class 0.000 claims description 8
- 238000006116 polymerization reaction Methods 0.000 claims description 8
- 239000001205 polyphosphate Substances 0.000 claims description 8
- 235000011176 polyphosphates Nutrition 0.000 claims description 8
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims description 8
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 8
- 238000005054 agglomeration Methods 0.000 claims description 7
- 230000002776 aggregation Effects 0.000 claims description 7
- 229940105329 carboxymethylcellulose Drugs 0.000 claims description 7
- 229940045110 chitosan Drugs 0.000 claims description 7
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims description 7
- 229940033080 omega-6 fatty acid Drugs 0.000 claims description 7
- 229960000292 pectin Drugs 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021588 free fatty acids Nutrition 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims 3
- 150000001982 diacylglycerols Chemical class 0.000 claims 2
- 241000978776 Senegalia senegal Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 abstract description 13
- 239000011159 matrix material Substances 0.000 abstract description 5
- 235000019198 oils Nutrition 0.000 description 37
- 239000003921 oil Substances 0.000 description 35
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 20
- 244000005700 microbiome Species 0.000 description 16
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 15
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 229940090949 docosahexaenoic acid Drugs 0.000 description 10
- 239000008188 pellet Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 244000215068 Acacia senegal Species 0.000 description 7
- 241000251468 Actinopterygii Species 0.000 description 7
- 235000019688 fish Nutrition 0.000 description 7
- 235000003599 food sweetener Nutrition 0.000 description 7
- 239000003765 sweetening agent Substances 0.000 description 7
- 239000004368 Modified starch Substances 0.000 description 6
- 229920000881 Modified starch Polymers 0.000 description 6
- 239000000416 hydrocolloid Substances 0.000 description 6
- 235000019426 modified starch Nutrition 0.000 description 6
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical group CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 5
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- -1 pyritramide Chemical compound 0.000 description 5
- 241000199912 Crypthecodinium cohnii Species 0.000 description 4
- 241000235575 Mortierella Species 0.000 description 4
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 235000021323 fish oil Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 241000195493 Cryptophyta Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241000907999 Mortierella alpina Species 0.000 description 3
- 241000598397 Schizochytrium sp. Species 0.000 description 3
- 239000004383 Steviol glycoside Substances 0.000 description 3
- 241001467333 Thraustochytriaceae Species 0.000 description 3
- 241000233675 Thraustochytrium Species 0.000 description 3
- 230000001055 chewing effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 125000004494 ethyl ester group Chemical group 0.000 description 3
- 239000008369 fruit flavor Substances 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000000845 maltitol Substances 0.000 description 3
- 235000010449 maltitol Nutrition 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000006014 omega-3 oil Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 229930182488 steviol glycoside Natural products 0.000 description 3
- 235000019411 steviol glycoside Nutrition 0.000 description 3
- 150000008144 steviol glycosides Chemical class 0.000 description 3
- 235000019202 steviosides Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 2
- 241000199913 Crypthecodinium Species 0.000 description 2
- 241000199914 Dinophyceae Species 0.000 description 2
- 108700035965 MEG3 Proteins 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- 241000235395 Mucor Species 0.000 description 2
- IDBPHNDTYPBSNI-UHFFFAOYSA-N N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide Chemical compound C1CN(CCN2C(N(CC)N=N2)=O)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 IDBPHNDTYPBSNI-UHFFFAOYSA-N 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 2
- 102100023075 Protein Niban 2 Human genes 0.000 description 2
- 241000233639 Pythium Species 0.000 description 2
- ZTVQQQVZCWLTDF-UHFFFAOYSA-N Remifentanil Chemical compound C1CN(CCC(=O)OC)CCC1(C(=O)OC)N(C(=O)CC)C1=CC=CC=C1 ZTVQQQVZCWLTDF-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241001125048 Sardina Species 0.000 description 2
- 241000233671 Schizochytrium Species 0.000 description 2
- 241001491678 Ulkenia Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229960001391 alfentanil Drugs 0.000 description 2
- 229960001736 buprenorphine Drugs 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 229960004126 codeine Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- WDEFBBTXULIOBB-WBVHZDCISA-N dextilidine Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)OCC)CCC=C[C@H]1N(C)C WDEFBBTXULIOBB-WBVHZDCISA-N 0.000 description 2
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 2
- 229960000240 hydrocodone Drugs 0.000 description 2
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 description 2
- 229960001410 hydromorphone Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- USSIQXCVUWKGNF-QGZVFWFLSA-N levomethadone Chemical compound C=1C=CC=CC=1C(C[C@@H](C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-QGZVFWFLSA-N 0.000 description 2
- 229960002710 levomethadone Drugs 0.000 description 2
- 229960001797 methadone Drugs 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 229960000805 nalbuphine Drugs 0.000 description 2
- NETZHAKZCGBWSS-CEDHKZHLSA-N nalbuphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]1(O)CC[C@@H]3O)CN2CC1CCC1 NETZHAKZCGBWSS-CEDHKZHLSA-N 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229960002085 oxycodone Drugs 0.000 description 2
- 229960005118 oxymorphone Drugs 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- 239000010773 plant oil Substances 0.000 description 2
- 229960003394 remifentanil Drugs 0.000 description 2
- 235000019512 sardine Nutrition 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 229960001402 tilidine Drugs 0.000 description 2
- 229960004380 tramadol Drugs 0.000 description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 2
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- 241000235349 Ascomycota Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241001306132 Aurantiochytrium Species 0.000 description 1
- 241000206761 Bacillariophyta Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 241001138693 Botryochytrium Species 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000195628 Chlorophyta Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 241000206751 Chrysophyceae Species 0.000 description 1
- 241000222290 Cladosporium Species 0.000 description 1
- 241000252203 Clupea harengus Species 0.000 description 1
- 241001454694 Clupeiformes Species 0.000 description 1
- 241001480517 Conidiobolus Species 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 241001480508 Entomophthora Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 241001219832 Lobosporangium Species 0.000 description 1
- 241001417902 Mallotus villosus Species 0.000 description 1
- 241000276489 Merlangius merlangus Species 0.000 description 1
- 241001306135 Oblongichytrium Species 0.000 description 1
- 241000238413 Octopus Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 241000233614 Phytophthora Species 0.000 description 1
- 241001600434 Plectroglyphidodon lacrymatus Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000197220 Pythium insidiosum Species 0.000 description 1
- 241000223252 Rhodotorula Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241000233667 Saprolegnia Species 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 241000238371 Sepiidae Species 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241001223864 Sphyraena barracuda Species 0.000 description 1
- 241001466451 Stramenopiles Species 0.000 description 1
- 241000276707 Tilapia Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000269959 Xiphias gladius Species 0.000 description 1
- 235000019513 anchovy Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 235000019514 herring Nutrition 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- BJHIKXHVCXFQLS-UYFOZJQFSA-N keto-D-fructose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-UYFOZJQFSA-N 0.000 description 1
- 229940106134 krill oil Drugs 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 102000051367 mu Opioid Receptors Human genes 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- GGCSSNBKKAUURC-UHFFFAOYSA-N sufentanil Chemical compound C1CN(CCC=2SC=CC=2)CCC1(COC)N(C(=O)CC)C1=CC=CC=C1 GGCSSNBKKAUURC-UHFFFAOYSA-N 0.000 description 1
- 229960004739 sufentanil Drugs 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 235000021335 sword fish Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 description 1
- 229960005126 tapentadol Drugs 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 239000010698 whale oil Substances 0.000 description 1
- 108020001612 μ-opioid receptors Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/70—Fixation, conservation, or encapsulation of flavouring agents
- A23L27/72—Encapsulation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5052—Proteins, e.g. albumin
- A61K9/5057—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18166672.8 | 2018-04-10 | ||
| EP18166672 | 2018-04-10 | ||
| PCT/EP2019/059005 WO2019197432A1 (en) | 2018-04-10 | 2019-04-10 | Multiparticulate solid dosage form having an elastic texture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020020567A2 true BR112020020567A2 (pt) | 2021-01-12 |
Family
ID=61965824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020020567-2A BR112020020567A2 (pt) | 2018-04-10 | 2019-04-10 | Forma de dosagem sólida de múltiplos particulados que tem uma textura elástica |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210030681A1 (https=) |
| EP (1) | EP3773521A1 (https=) |
| JP (1) | JP2021519798A (https=) |
| KR (1) | KR20200143697A (https=) |
| CN (1) | CN111936123A (https=) |
| BR (1) | BR112020020567A2 (https=) |
| TW (1) | TW201943410A (https=) |
| WO (1) | WO2019197432A1 (https=) |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0952850A (ja) * | 1995-06-09 | 1997-02-25 | Meiji Seika Kaisha Ltd | グミ製剤 |
| US6974592B2 (en) | 2002-04-11 | 2005-12-13 | Ocean Nutrition Canada Limited | Encapsulated agglomeration of microcapsules and method for the preparation thereof |
| KR20080055788A (ko) * | 2005-07-07 | 2008-06-19 | 오션 뉴트리션 캐나다 리미티드 | 이송 장치가 구비된 식품 및 이의 제조를 위한 방법 |
| RU2008112212A (ru) * | 2005-08-30 | 2009-10-10 | Фирмениш Са (Ch) | Инкапсулированные активные ингредиенты, способы их получения и применение |
| DE102006021280A1 (de) | 2006-05-05 | 2007-11-08 | Innogel Ag | Modifiziertes Mogul Verfahren |
| KR100758664B1 (ko) * | 2006-08-16 | 2007-09-13 | (주)케비젠 | 불포화지방산 함유 마이크로캡슐의 제조방법, 이 방법에의해 제조된 마이크로캡슐 및 이를 포함하는 제품 |
| KR20100047869A (ko) | 2007-07-19 | 2010-05-10 | 디에스엠 아이피 어셋츠 비.브이. | 친유성 헬스 성분의 정제화가능한 배합물 |
| PL2057984T3 (pl) | 2007-11-09 | 2010-05-31 | Acino Pharma Ag | Tabletki z hydromorfonem o przedłużonym uwalnianiu |
| US8895093B2 (en) * | 2008-04-14 | 2014-11-25 | Cadbury Enterprises Pte Limited | Method for the production of jelly confectionery |
| CH700621A1 (de) | 2009-03-27 | 2010-09-30 | Innogel Ag | Verbessertes Mogul Verfahren. |
| CN104023727B (zh) * | 2011-10-28 | 2017-04-05 | 鲁美纳医药公司 | 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂 |
| EP2606879A1 (en) | 2011-12-21 | 2013-06-26 | Hexal AG | Multiple unit pellet tablet formulation comprising an opioid |
| US20150030718A1 (en) * | 2012-03-12 | 2015-01-29 | Aker Biomarine Antarctic As | Oxidixable fatty acid composition delivery form |
| CN103071437B (zh) * | 2012-10-09 | 2015-02-25 | 临沂宝力佳食品有限公司 | 二十二碳六烯酸微胶囊二次包埋方法 |
| ES3005432T3 (en) * | 2014-08-05 | 2025-03-14 | Advanced Bionutrition Corp | Composition comprising hydrophobic biologically active compounds and method for preparing said composition |
-
2019
- 2019-04-09 TW TW108112367A patent/TW201943410A/zh unknown
- 2019-04-10 JP JP2020553655A patent/JP2021519798A/ja active Pending
- 2019-04-10 CN CN201980024374.8A patent/CN111936123A/zh active Pending
- 2019-04-10 US US17/046,107 patent/US20210030681A1/en not_active Abandoned
- 2019-04-10 WO PCT/EP2019/059005 patent/WO2019197432A1/en not_active Ceased
- 2019-04-10 KR KR1020207031629A patent/KR20200143697A/ko not_active Withdrawn
- 2019-04-10 EP EP19715932.0A patent/EP3773521A1/en not_active Withdrawn
- 2019-04-10 BR BR112020020567-2A patent/BR112020020567A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TW201943410A (zh) | 2019-11-16 |
| CN111936123A (zh) | 2020-11-13 |
| WO2019197432A1 (en) | 2019-10-17 |
| KR20200143697A (ko) | 2020-12-24 |
| EP3773521A1 (en) | 2021-02-17 |
| US20210030681A1 (en) | 2021-02-04 |
| JP2021519798A (ja) | 2021-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2808610C (en) | Process of manufacturing a stable softgel capsule containing microencapsulated probiotic bacteria | |
| CA2640529C (en) | Chewable capsules | |
| US20120301546A1 (en) | Acid-resistant soft gel compositions | |
| EP2825057B1 (en) | Oxidixable fatty acid composition delivery form | |
| CN102552213A (zh) | 无缝胶囊 | |
| KR20040105865A (ko) | 마이크로캡슐의 캡슐화된 응집체 및 그의 제조 방법 | |
| JP6313765B2 (ja) | 医薬組成物 | |
| JPWO2005102291A1 (ja) | 水溶性活性成分含有シームレスカプセル | |
| CN100399935C (zh) | 咀嚼性胶囊及其制造方法 | |
| BR112020020567A2 (pt) | Forma de dosagem sólida de múltiplos particulados que tem uma textura elástica | |
| US20210015753A1 (en) | Freeze-dried multiparticulate solid dosage form | |
| CA2858234C (en) | Stable formulations of antiplatelet agents, omega-3 fatty acids and amylose in soft gelatin capsules | |
| JP7222548B2 (ja) | 三層構造シームレスカプセル | |
| CN1708290A (zh) | 含有稳定胆碱的剂型及其制备方法 | |
| EA051709B1 (ru) | Стабильная пищевая микрокапсула для доставки нестабильных и несовместимых с пищей активных ингредиентов в пищевые продукты | |
| JP2021519798A5 (https=) | ||
| WO2020221573A1 (en) | New delivery system for polyunsaturated fatty acids | |
| JPWO2019197432A5 (https=) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2770 DE 06-02-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |